IMed Group, a prominent provider of expert services to the global medical and health technology sector, has appointed Parminder Kalle as its new Chief Commercial Officer. This strategic move underscores IMed Group’s commitment to enhancing its global footprint and service offerings.
With over two decades of experience in medical devices, in vitro diagnostics, pharmaceuticals, and digital health, Parminder Kalle combines technical acumen with a robust commercial leadership track record. In his new role, he will spearhead IMed Group’s business development and strategic growth initiatives on a global scale.
Parminder’s mandate is clear: accelerate international growth, forge strategic partnerships, and enhance the integration of IMed Group’s quality, regulatory, and clinical services. His focus is on establishing IMed Group as a trusted global partner that not only ensures compliance but also delivers value through innovation, insight, and operational agility.
As Chief Commercial Officer, Parminder will oversee all commercial operations, concentrating on quality, regulatory, and clinical services. His strategy emphasises a balance of technical excellence and commercial agility, leveraging deep insights into regulatory landscapes, reimbursement pathways, and market access strategies. This approach aims to deliver services that are both technically robust and strategically aligned with clients’ business objectives. Throughout his career, Parminder has successfully blended technical knowledge with commercial strategy, ensuring clients navigate regulatory and quality frameworks efficiently, turning these into competitive advantages.
“IMed Group is entering an exciting phase of evolution,” Parminder stated. “Our strength lies in combining deep regulatory expertise with commercial strategy. My focus is on driving growth through meaningful partnerships and helping our clients adapt quickly to industry change, turning compliance and quality into a platform for long-term success.”
Parminder Kalle’s appointment is a pivotal step in IMed Group’s strategy to bolster its market position and expand its service portfolio. This move is part of IMed’s broader plan to scale global operations and enhance its comprehensive service offerings across the Medtech sector.
Leeanne Baker, CEO of IMed Group, remarked, “Parm brings a rare combination of technical expertise, commercial acumen, and international experience. His appointment strengthens our ability to deliver innovative, client-focused solutions across the global life sciences sector. We are confident that his leadership will enable IMed Group to grow further while continuing to provide outstanding support to our clients.”
Founded in 2012, IMed Consultancy offers a wide range of expert services to the global medical and health technology industry. The company supports medical device and in vitro medical device manufacturers in driving innovation and improving patient care worldwide, providing assistance throughout the product lifecycle from concept and design to clinical studies and post-market surveillance.
IMed Consultancy’s team of highly skilled medical regulatory professionals is committed to innovation, client growth, and success. The company builds trusted relationships by offering agile solutions and education to advance healthcare innovations, adapting flexibly to client needs, and investing in developing knowledge to deliver value to the sector. With over 70 years of combined expertise, IMed ensures client devices are launched and maintained in compliance globally, including in the UK and EU.
